TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Elekta AB ( ($SE:EKTA.B) ) has issued an announcement.
Elekta AB reported a 1% increase in net sales at constant exchange rates for the second quarter of 2025/26, driven by strong performance in Europe. The company is implementing a new operating model to enhance product development and operational efficiency, aiming for SEK 500 million in annual cost savings by Q1 2026/27. Additionally, Elekta has conducted an order review, resulting in the cancellation of SEK 2,197 million in orders to improve predictability and profitability. The company plans to simplify its organizational structure, reduce its global workforce, and focus on innovation and customer-centric strategies to regain market share.
The most recent analyst rating on ($SE:EKTA.B) stock is a Sell with a SEK41.50 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta AB operates in the medical technology industry, focusing on providing advanced solutions for cancer and brain disorders treatment. The company is known for its innovative product portfolio, including radiotherapy and radiosurgery systems, and has a strong market presence in Europe and other regions.
Average Trading Volume: 1,207,827
Technical Sentiment Signal: Sell
Current Market Cap: SEK16.6B
For detailed information about EKTA.B stock, go to TipRanks’ Stock Analysis page.